Jun 15, 2020
AbbVie to Showcase 27 Studies at the Virtual 2020 Annual Scientific Meeting of the American Headache Society
Apr 02, 2020
COVID-19 Pandemic in the US May Curtail Uptake of Recent Acute Migraine Market Entrants, Diminishing Specialists' Prelaunch Expectations that Biohaven's Nurtec ODT Would Challenge Allergan's Ubrelvy and Eli Lilly's Reyvow
Mar 25, 2020
2020 Insights into Calcitonin Gene Related Peptide Type 1 Receptor - Featuring Adepthera, Allergan and Amgen Among Others
Dec 18, 2019
Amgen/Novartis' Aimovig Label Revision and Teva's Ajovy Autoinjector Delay Clear the Way for Continued Growth of Eli Lilly's Emgality in the US Migraine Prevention Market, According to Spherix Global Insights
Oct 17, 2019
Prime Therapeutics Study Finds Use, Costs for New Migraine Prevention Medications Projected to Triple by 2020
Sep 26, 2019
Strong Uptake in the Expanding Preventive-Treated Episodic Migraine Segment Has Propelled Eli Lilly's Third-to-Market Emgality to Second Place in the Anti-CGRP Class Surpassing Teva's Ajovy
Sep 11, 2019
Unimpeded by Allergan's Botox Dominance, Amgen/Novartis' Aimovig, Teva's Ajovy, and Eli Lilly's Emgality Use at the Patient Level is More Robust Within the Episodic Migraine Segment Than Physicians Are Aware of
May 02, 2019
Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting
Mar 25, 2019
Spherix Global Insights' Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva's Ajovy Early Launch Success
Oct 17, 2018
Express Scripts Offers New Value-Based Program for Migraine
Jun 28, 2018
Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig(TM) (erenumab-aooe) In Patients With Chronic And Episodic Migraine
May 17, 2018
FDA approves novel preventive treatment for migraine
May 17, 2018
FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Apr 17, 2018
When Others Fail, New Migraine Treatment May Work
Jan 22, 2018
Amgen Reports Aimovig(TM) (Erenumab) Met All Primary And Secondary Endpoints In Unique Phase 3b Study In Episodic Migraine Patients Who Have Failed Multiple Prior Preventive Treatments
Nov 29, 2017
Aimovig(TM) (erenumab) Phase 3 STRIVE Data Published In The New England Journal Of Medicine Demonstrate Significant, Sustained Efficacy In Migraine Prevention
Nov 27, 2017
Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
Nov 20, 2017
PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2026
Nov 16, 2017
Biohaven Completes Enrollment In The First Of Two Pivotal Phase 3 Clinical Trials Of Rimegepant, A Second Generation Oral CGRP-Receptor Antagonist, For The Acute Treatment Of Migraine
Sep 07, 2017
New Data Demonstrate Aimovig(TM) (erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies